Organizations
Organization | Regulated Trials | Results on time (%) | Results late (%) | Results unreported (%) |
|---|---|---|---|---|
| Novartis | 336 | 12 % ( 40 ) | 79 % ( 267 ) | 9 % ( 30 ) |
| National Institutes of Health Clinical Center (CC) | 252 | 22 % ( 55 ) | 71 % ( 180 ) | 8 % ( 21 ) |
| M.D. Anderson Cancer Center | 249 | 20 % ( 51 ) | 70 % ( 175 ) | 10 % ( 24 ) |
| Pfizer | 187 | 16 % ( 29 ) | 82 % ( 153 ) | 5 % ( 10 ) |
| Wake Forest University Health Sciences | 177 | 10 % ( 17 ) | 69 % ( 122 ) | 23 % ( 40 ) |
| Gilead Sciences | 166 | 13 % ( 21 ) | 87 % ( 144 ) | 1 % ( 2 ) |
| University of California, San Francisco | 156 | 12 % ( 19 ) | 71 % ( 111 ) | 17 % ( 27 ) |
| Stanford University | 154 | 10 % ( 16 ) | 77 % ( 118 ) | 14 % ( 22 ) |
| Hoffmann-La Roche | 151 | 11 % ( 17 ) | 79 % ( 120 ) | 9 % ( 14 ) |
| Mayo Clinic | 151 | 39 % ( 59 ) | 46 % ( 70 ) | 15 % ( 23 ) |
| Sanofi | 141 | 11 % ( 16 ) | 82 % ( 115 ) | 9 % ( 13 ) |
| Duke University | 139 | 18 % ( 25 ) | 60 % ( 84 ) | 22 % ( 31 ) |
| Eli Lilly and Company | 135 | 10 % ( 13 ) | 85 % ( 115 ) | 5 % ( 7 ) |
| AbbVie | 134 | 14 % ( 19 ) | 74 % ( 99 ) | 12 % ( 16 ) |
| Bristol-Myers Squibb | 134 | 6 % ( 8 ) | 84 % ( 113 ) | 10 % ( 13 ) |
| Massachusetts General Hospital | 131 | 7 % ( 9 ) | 59 % ( 77 ) | 36 % ( 47 ) |
| Takeda | 126 | 20 % ( 25 ) | 76 % ( 96 ) | 5 % ( 6 ) |
| GlaxoSmithKline | 122 | 29 % ( 35 ) | 68 % ( 83 ) | 6 % ( 7 ) |
| NYU Langone Health | 119 | 9 % ( 11 ) | 77 % ( 92 ) | 14 % ( 17 ) |
| Merck Sharp & Dohme LLC | 115 | 22 % ( 25 ) | 76 % ( 87 ) | 3 % ( 4 ) |
| AstraZeneca | 111 | 12 % ( 13 ) | 76 % ( 84 ) | 14 % ( 16 ) |
| Emory University | 106 | 5 % ( 5 ) | 81 % ( 86 ) | 14 % ( 15 ) |
| Janssen Research & Development, LLC | 106 | 5 % ( 5 ) | 76 % ( 81 ) | 19 % ( 20 ) |
| Bayer | 101 | 5 % ( 5 ) | 86 % ( 87 ) | 10 % ( 10 ) |
| Washington University School of Medicine | 97 | 15 % ( 15 ) | 70 % ( 68 ) | 15 % ( 15 ) |
| Columbia University | 94 | 6 % ( 6 ) | 57 % ( 54 ) | 37 % ( 35 ) |
| University of Alabama at Birmingham | 83 | 14 % ( 12 ) | 63 % ( 52 ) | 24 % ( 20 ) |
| Icahn School of Medicine at Mount Sinai | 81 | 7 % ( 6 ) | 72 % ( 58 ) | 21 % ( 17 ) |
| University of Pittsburgh | 79 | 18 % ( 14 ) | 56 % ( 44 ) | 28 % ( 22 ) |
| National Institute of Allergy and Infectious Diseases (NIAID) | 76 | 8 % ( 6 ) | 80 % ( 61 ) | 12 % ( 9 ) |
| Novo Nordisk A/S | 76 | 4 % ( 3 ) | 76 % ( 58 ) | 20 % ( 15 ) |
| VA Office of Research and Development | 75 | 12 % ( 9 ) | 84 % ( 63 ) | 4 % ( 3 ) |
| Allergan | 74 | 3 % ( 2 ) | 84 % ( 62 ) | 14 % ( 10 ) |
| The University of Texas Health Science Center, Houston | 74 | 3 % ( 2 ) | 81 % ( 60 ) | 16 % ( 12 ) |
| University of Washington | 72 | 3 % ( 2 ) | 82 % ( 59 ) | 15 % ( 11 ) |
| National Cancer Institute (NCI) | 70 | 14 % ( 10 ) | 87 % ( 61 ) | 20 % ( 14 ) |
| Montefiore Medical Center | 68 | 12 % ( 8 ) | 56 % ( 38 ) | 32 % ( 22 ) |
| University of Florida | 65 | 14 % ( 9 ) | 68 % ( 44 ) | 18 % ( 12 ) |
| University of Wisconsin, Madison | 65 | 17 % ( 11 ) | 78 % ( 51 ) | 12 % ( 8 ) |
| Dana-Farber Cancer Institute | 64 | 27 % ( 17 ) | 59 % ( 38 ) | 14 % ( 9 ) |
| Astellas Pharma Inc | 61 | 7 % ( 4 ) | 82 % ( 50 ) | 13 % ( 8 ) |
| Regeneron Pharmaceuticals | 60 | 3 % ( 2 ) | 85 % ( 51 ) | 13 % ( 8 ) |
| University of Colorado, Denver | 60 | 8 % ( 5 ) | 57 % ( 34 ) | 35 % ( 21 ) |
| University of Iowa | 58 | 5 % ( 3 ) | 74 % ( 43 ) | 21 % ( 12 ) |
| University of North Carolina, Chapel Hill | 58 | 59 % ( 34 ) | 29 % ( 17 ) | 12 % ( 7 ) |
| Amgen | 57 | 35 % ( 20 ) | 51 % ( 29 ) | 14 % ( 8 ) |
| Indiana University | 57 | 12 % ( 7 ) | 65 % ( 37 ) | 25 % ( 14 ) |
| Johns Hopkins University | 57 | 37 % ( 21 ) | 58 % ( 33 ) | 7 % ( 4 ) |
| University of Michigan | 57 | 12 % ( 7 ) | 84 % ( 48 ) | 4 % ( 2 ) |
| Weill Medical College of Cornell University | 57 | 40 % ( 23 ) | 49 % ( 28 ) | 12 % ( 7 ) |